The revival of psychedelic research today owes much to the respectability of its new advocates.
—Michael Pollan for The New Yorker, February 2015
Conference: Clinical Research Track
Clinical Research Track
Rick Doblin, Ph.D.
The Future of Psychedelic Therapy
Albert Garcia-Romeu, Ph.D.
Optimizing Psilocybin Dosing for Clinical Precision: The Case for Weight-Adjusted Dosing
Roland Griffiths, Ph.D.
Johns Hopkins Psilocybin Research Project: Studies of Mystical Experience, Adverse Effects, Meditation in Healthy Volunteers, and Palliative Effects in Cancer Patients
Stan Grof, M.D.
The Implications of Consciousness Research for Psychiatry, Psychology, and Psychotherapy
Breakthroughs in Psychedelic Research from the Beckley Foundation
Matthew W. Johnson, Ph.D.
Psychedelics as Behavior Change Agents: Addiction Recovery and Beyond
David Nutt, M.D.
Psychedelic Research at the Beckley/Imperial Research Programme
Stephen Ross, M.D., and Gabby Agin-Liebes, Ph.D. Candidate
Psilocybin for Cancer-Related Anxiety and Depression: NYU Phase 2 Randomized Controlled Trial and Proposed Mechanisms